Acute coronary syndrome (ACS) is one of the leading causes of admission to the emergency departments (EDs) worldwide. The diagnosis of ACS involves the evaluation of clinical signs and symptoms, electrocardiographic assessment, and measurement of cardiac circulating biomarkers. In the last 60 years, the use of laboratory markers has changed considerably. Early biomarker assessment has entailed testing for total enzyme activity of aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine kinase (CK) but was highly nonspecific. Soon thereafter, the development of immunoassays, as well as technical advances in automation, allowed the measurements of the CK MB isoenzyme (CK-MB) in mass rather than in activity and myoglobin. Currently, cardiac troponins (CTn) have the highest sensitivity and specificity for myocardial necrosis and represent the biochemical gold standard for diagnosing acute myocardial infarction (AMI). This review provides a chronology of the major events that marked the evolution of cardiac biomarker testing and the development of the relative assays from the first introduction of AST in the 1950s to the last high-sensitivity troponin immunoassays in the 2010s.
indices of assessments of AMI. In a subject having chest pain along with ECG changes, the elevation of cardiac biomarkers helps to diagnose non-ST segment elevation MI (NSTEMI) and STEMI. 2 The Joint European Society of Cardiology/American College of Cardiology 3 has proposed criteria for the diagnosis of AMI as shown in Table 1 .
It is estimated that 34% of all ACS events are repeat events, in line with recent data from the Global Registry of Acute Coronary Events (GRACE). 4 Coronary artery disease has assumed an epidemic proportion in India. Over 80% of deaths and 85% of disability from cardiovascular disease (CVD) occur in low-and middle-income countries. India is often considered to be the region with highest burden of CVD. 5 An interesting fact is that CAD affects Indians with greater frequency and at a younger age as compared with the developed countries, as well as many other developing countries.
WHY DO WE NEED BIOMARKERS FOR DIAGNOSIS?
Acute coronary syndrome is the result of numerous pathophysiological events like • Plaque rupture with acute thrombosis, • Progressive mechanical obstruction, • Inflammation, • Secondary unstable angina, and • Dynamic obstruction (coronary vasoconstriction). The cardiac biomarkers now help the physicians to understand the degree of inflammation, myocyte necrosis, vascular damage, and hemodynamic stress contributing to ACS. These levels of biomarkers noninvasively demonstrate the pathogenic changes in the heart (Graph 1). As seen in Graph 1, the detection of cTn in the blood of patients with ACS is indicative of myocardial necrosis with the presence of intracoronary thrombus and distal embolization of platelet microaggregates. 6 Necrosis
INTRODUCTION
Coronary artery disease (CAD) is the leading cause of death among adults and one of the most common reasons for ED visits. Although the standard 12-lead electrocardiogram (ECG) is the single best test to identify patients with acute ST segment elevation myocardial infarction (STEMI) upon ED presentation, it still has relatively low sensitivity (only 35-50%) for detection of AMI. 1 Cardiac biomarkers are measurable and quantifiable biological parameters which are detected in the blood and serve as compromises the integrity of the sarcolemmal membrane; intracellular macromolecules (serum and plasma cardiac markers) begin to diffuse into cardiac interstitium and ultimately into microvasculature and lymphatics. The rate of appearance of these macromolecules in the peripheral circulation depends on several factors, including intracellular location, molecular weight, local blood and lymphatic flow, and the rate of elimination from the blood. 7, 8 It is important to clarify that these tests of myocardial injury do not provide any direct insight to the cause of the damage; it may be due to nonischemic insults. 9 These sensitive biomarkers ( Fig. 1 ) guide the clinician in early management of myocardial ischemia to prevent necrosis with treatments, such as fibrinolysis, coronary artery bypass grafting, and percutaneous coronary interventions (PCIs) for improving outcomes.
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Criteria for IDEAL markers for MI • AST increases in blood 3 to 4 hours after AMI, reaches the maximum value in blood in 15 to 28 hours, and returns to normal values within 5 days. 13 However, despite the high sensitivity for AMI, AST is a nonspecific biomarker of cardiac tissue, wherein its activity can also increase in several other conditions including hepatic congestion secondary to congestive heart failure, myocarditis, electrical cardioversion, pericarditis, tachyarrhythmias, pulmonary embolism, and shock. 
1955: LDH
• A cytoplasmic enzyme found in skeletal, muscle, liver, heart, kidney, and red blood cells. It is not a 
1960: total creatinine kinase levels (sum of CK-MM, CK-MB, and CK-BB)
• It is a cytoplasmic and mitochondria enzyme of all body muscles. Thus, it is nonspecific to cardiac tissue (available in skeletal muscles also). It was in 1960 that the CK activity was shown to be a potential biomarker of cardiac muscle injury.
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• It gets elevated in 4 to 6 hours, peaks in 24 hours, and returns to normal values in approximately 72 hours 13 ; the sensitivity of this biomarker is very high when blood is collected early after the onset of disease. Sorensen reported a sensitivity of 98% in the AMI diagnosis when blood was collected within 72 hours after the onset of disease. 23 Moreover, he also demonstrated that patients with high CK activity measurement in the third day had a worse prognosis.
• Years later, it was shown that total CK activity may be related to the extent of MI and prognosis. 24, 25 • Various types are -CK-1 (BB): Brain -CK-2 (MB): Myocardium -CK-3 (MM): Skeletal muscle, heart • Limitations-nonspecific; it also gets elevated in any muscle disease, skeletal trauma, alcohol intoxication, seizures, vigorous exercise, thoracic outlet syndrome, kidney disease, and pulmonary embolism.
1972: CK-MB isoenzyme activity/mass
• In 1972, Roe et al 26 developed a zone electrophoresis method for the identification and quantification in serum or plasma of the CK-MB isoenzyme.
• The CK-MB isoenzyme, which is normally undetectable or very low in the blood, increases in both heart and skeletal diseases by showing highest concentration in cardiac muscle (~22% of the total CK content of myocardium compared with ~1 to 3% in the skeletal muscle).
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• Several studies confirmed that CK-MB subforms provide a reliable and specific diagnosis with high accuracy in the first hours of onset of cardiac symptoms. [28] [29] [30] Creatine kinase MB isoenzyme isoforms exist in only one form in cardiac muscle (CK-MB2) but exists in different isoforms in the plasma (CK-MB1).
• The mass method of CK-MB levels (that use monoclonal antibodies directed against CK-MB) has proved to be more accurate than traditionally radioimmunoassay or agarose gel electrophoresis methods, especially in patients presenting within 4 hours of injury. A study by Seo et al 31 compared
CK-MB mass vs CK-MB activity and concluded that CK-MB mass is more sensitive when CK-MB concentration is in the low range.
• Puleo et al 28 reported a sensitivity and specificity of 95.7 and 93.9% respectively, with a high positive predictive value and a high negative predictive value within 6 hours of infarction. It is more specific than total CK. Creatine kinase MB isoenzyme (CK-2) has the most specificity for cardiac muscle (>85%), as normal skeletal muscle contains only 1% CK-MB. But is less specific than TnI. Creatine kinase MB isoenzyme appears in blood within 4 to 6 hours of onset of attack, peaks in 12 to 24 hours, and returns to normal within 2 to 3 days. • One small study has shown a very high death rate (64%) during 4 years follow-up in patients who were admitted to the cardiac care unit with chest pain, positive CK-MB mass, and nondiagnostic ECG changes of STEMI. Several investigators have also studied the release of CK-MB mass following PCI. 32 They demonstrated that CK-MB mass is a sensitive indicator of myocardial injury following PCI. One study reported that 40% of patients showed evidence of myocardial damage following PCI using both CK-MB mass and cTnT. 33, 34 • Advantages: It is useful for early diagnosis of MI.
-It is useful for diagnosis of reinfarction • Disadvantages: It is not used for delayed admission (more than 2 days) It is not 100% specific (elevated in skeletal muscle damage, strenuous exercise in long distance runners).
Pearson et al in 1990, proposed use of CK-MB relative index (CK-MB/total CK) to improve its specificity. Ratios greater than 2.5% are considered suggestive of myocardial damage. Also, a level of MB2 > 1 U/L, and a ratio of MB2/ MB1 > 2.5 indicates myocardial injury at 6 hours. 35 
CTDT

CARDIAC PROTEINS
1978: myoglobin
• Myoglobin is an iron-and oxygen-binding protein found in muscle tissue. It is only found in the blood stream when it is released following muscle injury.
• In 1978, myoglobin was detected for the first time. 36, 37 It is a sensitive marker for muscle injury making it a potential marker for MI. It is not much specific for cardiac tissue (also found in skeletal muscles and renal tissue).
• Time sequence after infarction: It rises as fast as 2 hours, peaks at 6 to 8 hours, and returns to normal in 20 to 36 hours.
• Advantages: It has a high negative predictive value in early phase. It also has been used in assessing reperfusion after thromobolysis.
In a study by Bhayana et al, 38 myoglobin was found to be superior to CK-MB mass and TnT for ruling out AMI within the period of 3 to 6 hours after symptom onset.
• Disadvantages: Not for delayed admission cases (after 1 day of onset of attack) Have false positives with skeletal muscle injury and renal failure.
1971: troponin isoforms
• In 1971, Greaser and Gergely demonstrated that the troponin complex actually consists of three components which were named TnC, TnI, and TnT in light of their specific properties: Ca 2+ binding capacity (TnC), inhibition of ATPase activity (TnI), and tropomyosin binding respectively (TnT).
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• Cardiac-TnT (34 kDa) was first introduced in 1989 as a marker for AMI. 40 • Complex of three protein subunits: (Fig. 2 They are more specific for MI diagnosis (100% cardiac specific).
• 43 There is an incremental risk of death or MI in patients with elevated troponins that can be seen in a quantitative fashion, even in patients with chronic renal insufficiency. Despite using the latest generation assays and higher cut-off values (higher than the 99th percentile) cTnT and cTnI were positive in 82 and 6% of dialysis patients respectively. 44 Even patients in whom CK-MB levels are within normal limits, troponin elevation signifies an increased risk of death when compared with those without elevation. 43 • Serial measurements of cTn significantly improve the ability of this biomarker in detecting AMI. 45 Hamm et al 46 performed troponin testing upon presentation and at 4 hours with improvement in the sensitivity from 51 to 94% for cTnT and 66 to 100% for cTnI in patients without ST elevation. Higher diagnostic sensitivity and specificity require specimen collection at patient presentation, 6 to 9 hours later and at 12 to 24 hours if clinical suspicion is high and earlier results are negative.
• Elevated cTnT concentration has been reported in a significant number of patients with chronic renal failure. These levels do not seem to be affected by hemodialysis, with elevations persisting after treatment. 47 In chronic kidney disease (CKD) patients on hemodialysis without ACS, cTnI was reported to have better sensitivity and specificity for the diagnosis of AMI compared with cTnT, but positive cTnT was associated with increased all-cause mortality during follow-up. 48, 49 • Elevated cTnT in patients with non-STEMI is associated with poor prognosis. 43 The increase correlates well with the severity of coronary artery lesions determined by angiography. 50 In one important study, the prognostic value of cTnT was assessed in 967 patients with unstable angina. It was found that the group that had elevated concentrations of cTnT had an increased risk of cardiac events, and the higher the cTnT, the more frequent the complications. Patients were followed up for 6 months for cardiac complications. The risk of further AMI and death was 4.3% in patients with cTnT < 0.06 μg/L and 16.1% for those with cTnT ≥ 0.18 μg/L. 51 In another study by Stubbs et al, 52 62 non-STEMI patients were followed up for about 3 years after their admission with cTnT concentration ≥0.2 ng/mL. The incidence of complications in this group was very high: cardiac death (12 patients), coronary revascularization (22 patients), death and nonfatal AMI (18 patients).
• The Global Use of Strategies to Open Occluded
Coronary Arteries IV (GUSTO-IV) trial found that elevated troponin levels predicted short-term prognosis regardless of creatinine clearance. Patients with end-stage renal disease (ESRD) with elevated troponin levels had an increased risk of death after 1, 2, and 3 years of follow-up, and increase in troponin levels in ESRD patients showed a two-to fivefold increase in mortality. 
2010: highly sensitive cTn
• These are newer high-sensitivity assays that can enable more precise measurement of very low concentrations of cardiac-specific troponin, and experts recommend these to detect cTn in more than 50% of an apparently healthy population.
• Even low-level elevation of troponin detected with these sensitive assays is able to detect cardiac microinfarctions and is associated with worst prognosis.
2001: BNP and NT-proBNP
• These are used to diagnose and grade the severity of congestive heart failure. NT-proBNP is a marker in the blood for BNP, a hormone that rises during cardiac stress due to stretching of chambers of heart. • These mainly are used to differentiate between heart failure and lung disease (noncardiac) in the patients arriving in emergency with acute onset dyspnea.
• These also guide the monitoring of the effects of therapy for heart failure.
It is considered positive if its value is >100 ng/mL. Brain natriuretic peptide was prospectively studied as a biomarker of cardiovascular events in CKD patients in a community-based study in Japan. 54 The investigators collected baseline plasma BNP, serum creatinine, and urinary protein levels from 9,625 patients. The risk of cardiovascular events was significantly higher in participants with the highest BNP serum levels. In a study of 134 hemodialysis patients, Sommerer et al 55 found
that plasma levels of NT-proBNP were elevated in 100% and cTnT levels in approximately 40% of asymptomatic patients. Both increased NT-proBNP and cTNT were strongly associated with an adverse cardiovascular outcome (overall, there were 23 deaths due to MI and sudden cardiac death). From recent studies, it has emerged that the long-and short-term prognostic power of BNP and NT-proBNP is similar, in the AMI with ST elevation and without ST elevation, both at hospital admission and during hospitalization. 56 Brain natriuretic peptide and NT-proBNP have also emerged as prognostic indicators of long-term mortality early after an acute coronary event. This association was observed across the spectrum of ACS, including patients with STEMI, NSTEMI, and unstable angina (UA), those with or without elevated cTn, and those with or without clinical evidence of heart failure. 57, 58 Substudies of largescale clinical trials have evaluated the prognostic value of BNP and NT-proBNP in patients presenting with NSTE-ACS. [59] [60] [61] [62] [63] In all studies, elevated values of BNP and NT-proBNP have consistently been found. In a recent analysis made by the group of Sabatine, 60 in 450 patients of the OPUS-TIMI 14 and in 1,635 patients of the TACTICS-TIMI18 57 in which was investigated an approach with multiple markers in ACS without ST elevation, BNP, CRP, and cTnI were all independent predictors of adverse outcome. 60 The incidence of the adverse events not only correlated with the positivity of each marker but also with the number of positive markers, though patients with the worse prognosis (with a relative risk of death to 30 days between 6.0 and 13.0) were those with combined increase of levels of cTnI (marker of thrombosis and myocardial necrosis) of CRP (expression of inflammatory status), and of BNP (marker of myocardial dysfunction). Quite recently, plasma natriuretic peptide concentrations were also related to risk of cardiovascular events and death in apparently asymptomatic persons. 64 Recent data suggest that natriuretic peptides may help to better identify the very high risk patients and the very low risk ones among a population of ACS patients with respectively, positive or negative troponin. The role of BNP and NT-proBNP testing is included in the guidelines for the diagnosis and treatment of chronic heart failure of the taskforce of the European Society of Cardiology, published in 2005. Assessment of both markers is considered to be a reliable rule-out test of heart failure in primary care and in the emergency room. Assessment of BNP for risk stratification is also mentioned in the guidelines of the European Society of Cardiology for management of ACS in patients presenting without persistent ST segment elevation, but without any recommendations for the application of BNP and NT-proBNP in clinical routine. 65 Although originally BNP and NT-proBNP were considered biomarkers for heart failure only, now they are also considered biomarkers of myocardial ischemia. Elevated BNP and NT-proBNP levels have been observed in patients with stable CAD, in patients with UA, 66 and during and after PCI.
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RECOMMENDATIONS FOR USE OF BIOCHEMICAL MARKERS FOR DIAGNOSIS OF MI
• Recommended for all patients complaining of chest pain (with clinical examination and ECG) • Sample timing: on admission -3 to 6 hours later (only when uncertainty exists) • Test should be with low turnaround time:
-less than 1 hour (accepted) -less than half an hour is preferred • Types of markers used:
Early markers: as myoglobin and CK-MB; these appear in blood early (within <4 hours) but not specific and does not persist for long period (less than 2 days) Definitive markers: Troponin-it appears in blood later than myoglobin (within 6 hours) but 100% specific, prognostic, and stays longer (1 week 
CONCLUSION
The markers that are well suited for the early diagnosis of AMI within the time interval of 0 to 6 hours after symptom onset are myoglobin, H-FABP, and CK-MB isoforms. Although all have been shown to be excellent sensitive early markers, there are still significant issues concerning their specificity. Heart-type fatty acid-binding protein is more cardio-specific than myoglobin and the use of H-FABP as a marker for the early diagnosis of AMI seems preferable. Creatine kinase MB isoenzyme mass measurement is suitable in the 6 to 24 hours interval; CK-MB based on activity measurement is more sensitive in the 12 to 24 hours interval, and the other cardiac markers like total CK, cTnT, and cTnI are most reliable after 12 hours from symptom onset. The prolonged diagnostic window of cTn of several days that is highly sensitive and specific obviates the need for less specific markers with long diagnostic window like AST and CK. Decision-making regarding triage and treatment of patients should not be based on a single measurement of cardiac markers alone because of the time delay required for the marker to exceed the upper limit of reference range. Based on the recent recommendations by the ESC/ACC, cTnI and cTnT are the best markers for the confirmation of AMI. Creatine kinase MB isoenzyme (preferably mass) is the second best marker in the absence of troponin assays. Patients who present with acute chest pain suspicious of ACS are best managed within specifically designated units that have rapid access to specific equipment (ECG, echocardiogram) and facilities (point of care instruments to measure cardiac markers), and with appropriate staffing. A serial combination testing of a sensitive early marker (e.g., H-FABP, myoglobin, or CK-MB isoforms) and one of the cardiac-specific troponins (cTnT or cTnI) offers the best approach. Two serial testings within a minimum of 12 hours (e.g., at 0, 4-6, or 12 hours) after symptom onset provide reliable sensitivity and specificity for detecting ischemia and evolving infarction within the time interval required for the implementation of reperfusion therapy.
